TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Satisfactory completion of dosing in their initial study (Protocol 301012-CS5 \[NCT00607373\], 301012-CS7 \[NCT00706849\], 301012-CS17 \[NCT00477594\], or MIPO3500108 \[NCT00794664\])~Exclusion Criteria:~* Had any new condition or worsening of existing condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mipomersen (Type: EXPERIMENTAL): Mipomersen Sodium once a week for up to 4 years (depending on participant's consent). Participants were followed for additional 24 week post-treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Breathing and Walking Treatments on Recovery Post-Spinal Cord Injury

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults at least 18 years of age~* At least 12 months post-incomplete spinal cord injury (I-SCI), including but not limited to the following syndromes: Brown Sequard and Central Cord Syndromes~* Upper motor neuron lesion (with upper motor neuron signs (i.e. presence of clonus, spasms, and/or hyperreflexia))~* A diagnosis of first time SCI including etiology from trauma, vascular, or orthopedic pathology~* Resting oxygen saturation (SpO2) levels of 95-99%~* Individuals who ambulate independently, with an assistive device, or who can walk when provided manual assistance~* Persons using anti-spasticity medication must maintain stable medication dosage during the study~* Able to give informed consent.~* Medical approval by individual's physician~Exclusion Criteria:~* Current participation in a rehabilitation program/research protocol that could interfere or influence the outcome measures of the current study~* History of congenital SCI (e.g. myelomeningocele, intraspinal neoplasm, Frederich's ataxia) or other degenerative spinal disorders (e.g. spinocerebellar degeneration, syringomyelia) that may complicate the protocol~* Inappropriate or unsafe fit of the harness due to the participant's body size and/or joint contractures or severe spasticity that would prohibit the safe provision of either training modality.~* Severe spasticity that would prohibit the safe provision of training.~* Pregnancy - all women of childbearing age will be required to undergo pregnancy testing prior to enrollment~* Unstable medical condition that could interfere with safety during participation in study (i.e. symptomatic cardiopulmonary complication, osteoporosis, contractures or other significant medical complications that would prohibit or interfere with testing of walking function and training or alter compliance with a training protocol)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1 Arm (Pilot) (Type: EXPERIMENTAL): Individuals were exposed to intermittent hypoxia and locomotor training to establish our interventions (set up lab, train personnel, develop study protocols/interventions, etc)
- Phase 2 Arm (LTF) (Type: EXPERIMENTAL): Individuals were exposed to 10 days of intermittent hypoxia to determine the effect of this intervention on ventilatory long-term facilitation, as measured by minute ventilation
- Phase 3 Arm (Ventilatory Loading) (Type: OTHER): Individuals were exposed to 10 days of intermittent hypoxia to determine changes in ventilatory loading.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Suppression of Endometriosis With Progestins Before IVF-ET

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis of endometriosis~* body mass index \< 35 Kg/m2~Exclusion Criteria:~* if they have been already on long-term down-regulation of the pituitary gland with GnRHa for control of endometriosis~* liver or kidney disease~* evidence of diminished ovarian reserve (e.g. high FSH level \>12 IU/L or low AMH level \<1 ng/ml).

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Dienogest (Type: ACTIVE_COMPARATOR): None
- GnRH analogue (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Guided Epidural Block in Axial SPA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all participants fulfilled the ASAS criteria for axial SPA~* all participants under treatment including bDMARDS and sDMARDs beside NSAIDs~Exclusion Criteria:~* Naive patients not under treatment~* limitation of spine flexion due to non inflammatory causes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epidural block (Type: ACTIVE_COMPARATOR): Group I patients received caudal epidural injections with 1% lidocaine hydrochloride (xylocaine Astra Zeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
- control group (Type: NO_INTERVENTION): patients did not receive injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
* Diagnosis of candidemia and/or other forms of invasive candidiasis.~* Should not have received greater than 48 hours of systemic antifungal therapy.~* Life expectancy should be greater than 72 hours.~* Should not have received greater than one week of prophylactic azole therapy 30 days prior to enrollment

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* duration of type 1 diabetes longer than 12months,~* insulin pump therapy longer than 3 months,~* written informed consent to participate in the study signed by parents (and patient older than 16 years).~Exclusion Criteria:~* celiac disease,~* diabetes related complications (e.g. nephropathy),~* BMI at or above the 95th percentile and at or below 3rd percentiles for children and teenagers of the same age and sex,~* withdrawal of consent to participate in the study,~* comorbid conditions and treatment which could significantly affect glycemic values in the researchers' opinion.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Normal Bolus (Type: ACTIVE_COMPARATOR): Pre-breakfast insulin will be given as a Normal Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Normal Bolus will be calculated based on individual insulin-to-carbohydrate ratio (ICR).
- Super Bolus (Type: EXPERIMENTAL): Pre-breakfast insulin will be given as a Super Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Super Bolus will be calculated based on individual ICR increased to 150% and basal insulin will be suspended for 2 hours at the same time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Belimumab in Subjects With Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of SLE by ACR criteria.~* Active SLE disease.~* Autoantibody-positive.~* On stable SLE treatment regimen.~Key Exclusion Criteria:~* Pregnant or nursing~* Have received treatment with any B cell targeted therapy.~* Have received treatment with a biological investigational agent in the past year.~* Have received IV cyclophosphamide within 180 days of Day 0.~* Have severe lupus kidney disease.~* Have active central nervous system (CNS) lupus.~* Have required management of acute or chronic infections within the past 60 days.~* Have current drug or alcohol abuse or dependence.~* Have a historically positive test or test positive at screening for HIV, hepatitis B, or hepatitis C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Belimumab 1 mg/kg (Type: EXPERIMENTAL): Belimumab 1 mg/kg
- Belimumab 10 mg/kg (Type: EXPERIMENTAL): Belimumab 10 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Elderly Back Pain: Comparing Chiropractic to Medical Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 55 or older~* Idiopathic low back pain (LBP) of at least four weeks duration~* Meet the diagnostic classification of 1, 2, or 3 according to the Quebec Task Force on Spinal Disorders~Exclusion Criteria:~* Low back pain (LBP) not meeting Quebec Task Force Diagnostic Classifications 1, 2 or 3, especially LBP associated with: frank radiculopathy, altered lower extremity reflex, dermatomal sensory deficit, progressive unilateral muscle weakness or motor loss, symptoms of cauda equina compression, and CT or MRI evidence of anatomical pathology (e.g. abnormal disc, lateral or central stenosis.~* Co-morbid conditions or general poor health that could significantly complicate the prognosis of LBP, including pregnancy, bleeding disorders, extreme obesity, and clear evidence of narcotic or other drug abuse.~* Major clinical depression defined as scores greater that 29 on the Beck Depression Inventory - Second Edition~* Bone or joint pathology that contraindicate spinal manipulative therapy of joint pathology that contraindicate spinal manipulative therapy of the arthropathies and significant osteoporosis~* Pacemaker, because there are safety issues with equipment used to collect data in the biomechanical testing laboratory~* Current or pending litigation related to current episode of LBP.~* Receiving disability for any health-related condition~* Spinal Manipulative care for any reason within the past month~* Unwilling to postpone use of manual therapies for LBP except those provided in the study for the duration of the study period.~* Unable to read or verbally comprehend English.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HVLA-SM (Type: EXPERIMENTAL): High-velocity low amplitude spinal manipulation (HVLA-SM)
- LVVA-SM (Type: EXPERIMENTAL): Low-velocity variable amplitude spinal manipulation (LVVA-SM)
- Usual Medical Care (Type: ACTIVE_COMPARATOR): Usual medical care - (Celebrex, Aleve, Bextra, Naproxen)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~* Subjects who participated in study 580299-007.~* Written informed consent obtained from the subject prior to enrollment.~Exclusion Criteria:~* Use or planned use of any investigational or non-registered product other than the study vaccine.~* Decoding of the subject's 580299-001 treatment allocation to either the subject or the investigator.~* Administration or planned administration of any other HPV vaccine, other than the vaccine administered in study 580299-001.

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Cervarix Group (Type: EXPERIMENTAL): Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
- Placebo Group (Type: PLACEBO_COMPARATOR): Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is ≥ 18 years of age~* Subject has a diagnosis of immune (idiopathic) thrombocytopenic purpura per the American Society of Hematology guidelines~* If Subject is \> 60 years of age, subject has a written bone marrow aspiration and/or biopsy report consistent with a diagnosis of ITP~* Subject has received at least 1 prior therapy for ITP~* Subject's platelet count is ≤ 30,000 or the subject is experiencing bleeding that is uncontrolled with conventional therapies~* Subject (or legally-acceptable representative) is willing and able to provide written informed consent~Exclusion Criteria:~* Subject has a history of hematological malignancy, myeloproliferative disorder, myelodysplastic syndrome (MDS), or bone marrow stem cell disorder~* Subject has participated in any study evaluating PEG-rHuMGDF, recombinant human thrombopoietin (rHuTPO), or related platelet product~* Subject has a known hypersensitivity to any recombinant E coli-derived product~* Subject has received any therapeutic drug or device that is not approved by the local regulatory health agency for any indication within 4 weeks of Screening~* Subject is of reproductive potential and is not using adequate contraceptive precautions, in the judgment of the investigator~* Subject is pregnant or breast feeding~* Investigator has concerns regarding the subject's ability to comply with the protocol procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Romiplostim

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects \> or equal to 18 years of age.~* Presence of candidemia (positive blood culture) or invasive candidiasis (histopathologic or cytopathologic examination of a needle aspiration or biopsy specimen from a normally sterile site excluding mucous membranes showing yeast cells) obtained within the prior 96 hours of the screening visit.~* Subjects who received no more than one prior dose of an echinocandin or polyene.~Exclusion Criteria:~* Subjects with hypersensitivity to anidulafungin, other echinocandins or azoles.~* Presence of confirmed or suspected Candida osteomyelitis, endocarditis or meningitis.~* Subjects with infected prosthetic devices which cannot be removed within 24 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. (Type: EXPERIMENTAL): Subjects receive anidulafungin IV followed by oral therapy with fluconazole or voriconazole.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* COPD patients having at least one exacerbation within last year~* FEV1/FVC ratio (post-bronchodilator) ≤ 70%~* FEV1 (post-bronchodilator) ≤ 50% of predicted~Main Exclusion Criteria:~* COPD exacerbation not resolved at first baseline visit~* Diagnosis of asthma and/or other relevant lung disease

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: ACTIVE_COMPARATOR): 500 mcg, once daily, oral administration in the morning
- Placebo (Type: PLACEBO_COMPARATOR): once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males 18 years-of-age or older~* Stable, heterosexual relationship for at least 6 months~* A history of erectile dysfunction (ED) for at least 6 months~Exclusion Criteria:~* Any underlying cardiovascular condition, including unstable angina pectoris~* History of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to visit 1~* Uncontrolled atrial fibrillation / flutter at screening~* History of surgical prostatectomy for prostate cancer~* Hereditary degenerative retinal disorders~* History of loss of vision because of Non-arteritic anterior ischemic optic neuropathy (NAION), temporary or permanent loss of vision~* Presence of penile anatomical abnormalities~* Subjects who have been confirmed with phenylketonuria (PKU)~* Spinal cord injury~* Resting or postural hypotension or hypertension~* Subjects who are taking nitrates or nitric oxide donors, androgens, anti-androgens, alpha- blockers, medication known to prolong QT interval, Human immunodeficiency virus (HIV) protease inhibitors, itraconazole or ketoconazole, an clarithromycin and erythromycin~* Use of any treatment for ED within 7 days of Visit 1~* History of congenital QT prolongation~* History of syncope within the last 6 months prior to entry into the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vardenafil ODT (STAXYN, BAY38-9456) (Type: EXPERIMENTAL): Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete